Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, and Cognition in Post-Menopausal Women

NCT07705724 | Not Yet Recruiting

• 1 other identifier: 300136
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The study will examine the impact of adding two servings per day of skimmed or whole milk Greek yogurt on integrated muscle protein synthesis (iMPS), blood sugar control, and cognition in post-menopausal women with overweight and obesity.

Conditions

Obesity & Overweight; Women; Menopause

Keywords

Muscle Protein Synthesis; Protein Turnover; Glycemic Control; Cognition; Post-Menopause; Women; Protein; Dairy

Outcome Measures

Primary Outcomes (1)

• Integrated Muscle Protein Synthesis (iMPS)

  Integrated muscle protein synthesis expressed as the fractional synthetic rate (%/day).

  1 week

Secondary Outcomes (1)

• Glucose Homeostasis

  1 week

Other Outcomes (3)

• Plasma Essential Amino Acids (EAAs)

  Baseline to 30, 60, 90, 120, 150, 180, 210, and 240 minutes post yogurt ingestion

• Cognition: Reaction Time, Alertness, and Selective Attention

  Baseline to 1- and 4-hours post yogurt ingestion

• Cognition: Updating

  Baseline to 1- and 4-hours post yogurt ingestion

Study Arms (2)

Skimmed Milk Greek Yogurt

ACTIVE COMPARATOR

Participants will consume two servings per day of skimmed milk Greek yogurt.

Other: Skimmed vs Whole Milk Greek Yogurt

Whole Milk Greek Yogurt

ACTIVE COMPARATOR

Participants will consume two servings per day of whole milk Greek yogurt.

Other: Skimmed vs Whole Milk Greek Yogurt

Interventions

Skimmed vs Whole Milk Greek Yogurt OTHER

Participants will be randomized to receive a standardized diet with either skimmed milk or whole milk Greek yogurt.

Skimmed Milk Greek Yogurt; Whole Milk Greek Yogurt

Eligibility Criteria

• Age: 50 Years - 65 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 50 to 65 years
• Body mass index ≥25 to \<40 kg/m2 or body fat ≥36%
• Able to provide informed consent
• Absence of menstruation for ≥12 months without the use of hormonal contraceptives, or one of the following:
• Another medical cause of menopause e.g., history of bilateral oophorectomy
• Clinician-confirmed menopausal status for those with hysterectomy and retained/unknown ovaries
• Partial/total hysterectomy ≥12 months ago and current age ≥55 years

You may not qualify if:

• Allergy or intolerance to dairy products (other allergies or intolerances may be excluded if they are not compatible with the study meals and how they are prepared)
• Conditions, medications, or recent changes in medications that cause participants to be metabolically unstable (e.g., renal, cardiovascular, thyroid, polycystic ovary syndrome, type-1 and type-2 diabetes)
• Gastric bypass/bariatric surgery in the previous 5 years
• Pregnancy or nursing in the prior 12 months
• Weight loss or gain \>5 kg in the last two months
• Unable or unwilling to suspend use of blood thinning medications and non-steroidal anti-inflammatory drugs for the duration of the study
• Unwilling to abstain from vigorous exercise for the study period
• Does not or will not eat all foods on the standardized diet (e.g., allergies, intolerances, or taste preferences)
• Participants may be excluded at the Principal Investigator's discretion if their health or body composition is not compatible with the required study procedures

Sponsors & Collaborators

• University of Arkansas: lead
• National Dairy Council: collaborator

Study Sites (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

Location

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• David D Church, PhD

  University of Arkansas

  PRINCIPAL INVESTIGATOR

Central Study Contacts

David D. Church, PhD

CONTACT

501-526-5769; dchurch@uams.edu

Joseph J Matthews, PhD

CONTACT

501-526-5707; jmatthews@uams.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2026
• First Posted: July 15, 2026
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): October 1, 2028
• Study Completion (Estimated): April 1, 2029
• Last Updated: July 30, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)